Valuation : GlucoTrack

Market Cap 1.77M 1.52M 1.43M 1.3M 2.45M 169M 2.46M 16.92M 6.6M 85.16M 6.63M 6.48M 282M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -2.17M -1.87M -1.75M -1.6M -3.02M -208M -3.03M -20.82M -8.12M -105M -8.15M -7.98M -347M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
78.19%
Yield 2024 *
-
Yield 2025 -
1 day-1.47%
1 week-18.83%
Current month-40.88%
1 month-6.00%
3 months-56.62%
6 months-81.81%
Current year-92.71%
1 week 0.28
Extreme 0.279
0.35
1 month 0.28
Extreme 0.279
0.9
Current year 0.25
Extreme 0.25
4.24
1 year 0.25
Extreme 0.25
14.14
3 years 0.25
Extreme 0.25
5,939.99
5 years 0.25
Extreme 0.25
38,999.92
10 years 0.25
Extreme 0.25
468,000.47
Manager TitleAgeSince
Chief Executive Officer 55 14/07/2026
Director of Finance/CFO 66 28/01/2025
Chief Operating Officer - 01/02/2025
Director TitleAgeSince
Director/Board Member 59 27/08/2024
Director/Board Member 56 25/08/2023
Chairman 64 13/02/2024
Date Insider Type Main position Quantity % Market Cap.
26/03/25 Free

Director

4,490 0.0431%
25/03/25 Free

Director

8,747 0.0840%
25/03/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%-18.83%-93.44%-99.98% 1.77M
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.53%-2.84%+60.73%+91.34% 27.46B
Weighted average by Cap. -1.70%-1.06%+95.71%+133.63%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.47M -18.26M -16.67M -31.4M -2.16B -31.5M -217M -84.51M -1.09B -84.84M -82.99M -3.61B -19.39M -16.71M -15.66M -14.3M -26.94M -1.85B -27.02M -186M -72.51M -935M -72.79M -71.21M -3.1B
Net Debt -5.35M -4.61M -4.32M -3.95M -7.43M -511M -7.46M -51.28M -20.01M -258M -20.09M -19.65M -856M -3.94M -3.39M -3.18M -2.9M -5.47M -376M -5.49M -37.74M -14.72M -190M -14.78M -14.46M -630M
Logo GlucoTrack
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
28/08/26 $0.2820 -1.47% 2,652,291
27/08/26 $0.2862 -10.87% 1,692,958
26/08/26 $0.3211 -5.61% 574,581
25/08/26 $0.3402 +2.35% 562,154
24/08/26 $0.3324 -4.32% 224,483
  1. Stock Market
  2. Stocks
  3. GCTK Stock